TY - JOUR T1 - Epigenome-wide association study using prediagnostic bloods identifies a new genomic region (near <em>TMEM204 and IFT140</em>) associated with pancreatic cancer risk JF - medRxiv DO - 10.1101/2020.02.07.20021121 SP - 2020.02.07.20021121 AU - Dominique S. Michaud AU - Mengyuan Ruan AU - Devin C. Koestler AU - Dong Pei AU - Carmen J. Marsit AU - Immaculata De Vivo AU - Karl T. Kelsey Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/09/2020.02.07.20021121.abstract N2 - Background Epigenome-wide association studies (EWAS) using peripheral blood have identified specific sites of DNA methylation associated with risk of various cancers and may hold promise to identify novel biomarkers of risk; however, few studies have been performed for pancreatic cancer and none using a prospective study design.Methods Using a nested case-control study design, incident pancreatic cancer cases and matched controls were identified from participants who provided blood at baseline in three prospective cohort studies (Nurses’ Health Study, Health Professionals Follow-up Study and Physicians’ Health Study). DNA methylation levels were measured in DNA extracted from leukocytes using the Illumina MethylationEPIC array. Average follow-up period for this analysis was 13 years.Results A region in chromosome 16 near genesTMEM204 and IFT140 was identified as being differentially methylated in cases and controls. For some CpGs in the region, the associations were stronger with shorter time to diagnosis (e.g., OR= 5.95, 95% CI = 1.52-23.12, for top vs bottom quartile, for &lt;5 years between blood draw and cancer diagnosis) but associations remained significantly higher even when cases were diagnosed over 10 years after blood collection. Statistically significant differences in DNA methylation levels were also observed in the gastric secretion pathway using GSEA analysis.Conclusions Changes in DNA methylation in peripheral blood may mark alterations in metabolic or immune pathways (potentially including alterations in immune subtypes) that play a role in pancreatic cancer. Identifying new biological pathways in carcinogenesis of pancreatic cancer using EWAS approach could provide new opportunities for improving treatment and prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research reported in this publication was primarily supported by the NIH/National Cancer Institute grant R01 CA207110. In addition, other NIH funds contributed to the support of the investigators: R01 CA163451, and P30 CA168525, and the Kansas IDeA Network of Biomedical Research Excellence Bioinformatics Core, supported in part by the National Institute of General Medical Science (NIGMS) Award P20GM103418.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data from this study have been deposited in dbGAP and will be available on January 3, 2020 [“DNA Methylation Markers and Pancreatic Cancer Risk in 3 Cohort Studies (NHS, PHS, HPFS)” phs001917.v1.p1]. https://www.ncbi.nlm.nih.gov/projects/gapprev/gap/cgi-bin/study.cgi?study_id=phs001917.v1.p1 All data from this study have been deposited in dbGAP and will be available on January 3, 2020 [“DNA Methylation Markers and Pancreatic Cancer Risk in 3 Cohort Studies (NHS, PHS, HPFS)” phs001917.v1.p1]. https://www.ncbi.nlm.nih.gov/projects/gapprev/gap/cgi-bin/study.cgi?study_id=phs001917.v1.p1 ER -